1. Scrip

J&J Immunology President On Remicade, Inflectra And The Art Of Contract Negotiations

 
• By Jessica Merrill

Janssen Biotech's Immunology President Scott White defended the company's Remicade contracting strategy in an interview and outlined why J&J believes it has been unfairly targeted in an anti-competitive lawsuit filed by rival Pfizer.

Man with report

Biosimilars are not small molecule generic drugs and therefore generic-like commercial dynamics should not be expected in the biosimilar market: that's the crux of Johnson & Johnson's justification for tough contract negotiations with payers for Remicade (infliximab), which rival Pfizer Inc. says have unfairly blocked its biosimilar Inflectra (infliximab-dyyb).

J&J's Janssen Biotech Immunology President Scott White talked with Scrip Oct. 11 about the commercial dynamics in the infliximab market following the launch of the first biosimilar last year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.